Your browser doesn't support javascript.
loading
Homozygosity for a stop-gain variant in CCDC201 causes primary ovarian insufficiency.
Oddsson, Asmundur; Steinthorsdottir, Valgerdur; Oskarsson, Gudjon R; Styrkarsdottir, Unnur; Moore, Kristjan H S; Isberg, Salvor; Halldorsson, Gisli H; Sveinbjornsson, Gardar; Westergaard, David; Nielsen, Henriette Svarre; Fridriksdottir, Run; Jensson, Brynjar O; Arnadottir, Gudny A; Jonsson, Hakon; Sturluson, Arni; Snaebjarnarson, Audunn S; Andreassen, Ole A; Walters, G Bragi; Nyegaard, Mette; Erikstrup, Christian; Steingrimsdottir, Thora; Lie, Rolv T; Melsted, Pall; Jonsdottir, Ingileif; Halldorsson, Bjarni V; Thorleifsson, Gudmar; Saemundsdottir, Jona; Magnusson, Olafur Th; Banasik, Karina; Sorensen, Erik; Masson, Gisli; Pedersen, Ole Birger; Tryggvadottir, Laufey; Haavik, Jan; Ostrowski, Sisse Rye; Stefansson, Hreinn; Holm, Hilma; Rafnar, Thorunn; Gudbjartsson, Daniel F; Sulem, Patrick; Stefansson, Kari.
Afiliação
  • Oddsson A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Steinthorsdottir V; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Oskarsson GR; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Styrkarsdottir U; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Moore KHS; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Isberg S; Department of Anthropology, University of Iceland, Reykjavik, Iceland.
  • Halldorsson GH; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sveinbjornsson G; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Westergaard D; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Nielsen HS; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Fridriksdottir R; Methods and Analysis, Statistics Denmark, Copenhagen, Denmark.
  • Jensson BO; Department of Obstetrics and Gynecology, Copenhagen University Hospital, Hvidovre, Denmark.
  • Arnadottir GA; Department of Obstetrics and Gynecology, Copenhagen University Hospital, Hvidovre, Denmark.
  • Jonsson H; Department of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.
  • Sturluson A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Snaebjarnarson AS; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Andreassen OA; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Walters GB; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Nyegaard M; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Erikstrup C; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Steingrimsdottir T; NORMENT Centre, University of Oslo, Oslo, Norway.
  • Lie RT; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Melsted P; KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo, Oslo, Norway.
  • Jonsdottir I; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Halldorsson BV; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
  • Thorleifsson G; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
  • Saemundsdottir J; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Magnusson OT; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Banasik K; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Sorensen E; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Masson G; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Pedersen OB; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Tryggvadottir L; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Haavik J; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Ostrowski SR; School of Technology, Reykjavik University, Reykjavik, Iceland.
  • Stefansson H; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Holm H; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Rafnar T; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sulem P; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Stefansson K; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Nat Genet ; 56(9): 1804-1810, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39192094
ABSTRACT
Age at menopause (AOM) has a substantial impact on fertility and disease risk. While many loci with variants that associate with AOM have been identified through genome-wide association studies (GWAS) under an additive model, other genetic models are rarely considered1. Here through GWAS meta-analysis under the recessive model of 174,329 postmenopausal women from Iceland, Denmark, the United Kingdom (UK; UK Biobank) and Norway, we study low-frequency variants with a large effect on AOM. We discovered that women homozygous for the stop-gain variant rs117316434 (A) in CCDC201 (p.(Arg162Ter), minor allele frequency ~1%) reached menopause 9 years earlier than other women (P = 1.3 × 10-15). The genotype is present in one in 10,000 northern European women and leads to primary ovarian insufficiency in close to half of them. Consequently, homozygotes have fewer children, and the age at last childbirth is 5 years earlier (P = 3.8 × 10-5). The CCDC201 gene was only found in humans in 2022 and is highly expressed in oocytes. Homozygosity for CCDC201 loss-of-function has a substantial impact on female reproductive health, and homozygotes would benefit from reproductive counseling and treatment for symptoms of early menopause.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Ovariana Primária / Estudo de Associação Genômica Ampla / Homozigoto Limite: Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Ovariana Primária / Estudo de Associação Genômica Ampla / Homozigoto Limite: Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article